Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The REVEAL Trial aims to assess the efficacy, safety and tolerability of two bortezomib-based combination chemotherapy regimens: VD (bortezomib [Velcade], and dexamethasone) and CVD (cyclophosphamide, bortezomib [Velcade] and dexamethasone) in a randomized parallel phase II design in patients with AL amyloidosis who have Mayo stage II or III disease.
Critère d'inclusion
- Systemic AL-Amyloidosis